Pegylated Liposomal Doxorubicin (PLD) is one of the basic chemotherapeutics used in treatment of ovarian cancer in the second and subsequent line therapy. Looking for prognostic and predictive factors toselect the most effective treatment method is essential.The aim of this study was to evaluate the predictive and prognostic significance of polymorphism in 571 position of amino acid of TOP2A (topoisomerase II alpha gene). Material and methods. The consecutive 67 patients with diagnosed ovarian cancer, treated with PLD in the Oncology Clinical Hospital of the Military Medical Institute between March 2006 and December 2014 and fulfilling the study criteria, underwent retrospective analysis. Upon careful screening of the NCBI SNP database (http://www.ncbi.nlm.nih.gov), the authors found that rs144 622 532 gene variant is of top significance. The median PFS was 11.58 months, while the median OS was 18.88 months. No polymorphism was found in any of paraffin blocks from the patients. All the patients proved to be homozygous. Conclusion. Lack of the polymorphism in 571 position of amino acid of the TOP2A gene has no predictive or prognostic values in patients with ovarian cancer treated with PLD.